Literature DB >> 24920779

When does 2 plus 2 equal 5? A review of antimicrobial synergy testing.

Christopher D Doern1.   

Abstract

In this age of emerging antibiotic resistance, limited therapeutic options exist for treating multidrug-resistant organisms. Combination therapy is commonly employed to manage these infections despite little laboratory guidance as to the efficacy of this approach. Synergy testing methods have been used to assess the interaction of antibiotic combinations in vitro. This review will discuss the four primary methods used to assess synergy, as well as the data that exist for testing of cystic fibrosis. In the final analysis, this review concludes that there is not enough evidence to endorse synergy testing for routine clinical use.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24920779      PMCID: PMC4313275          DOI: 10.1128/JCM.01121-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.

Authors:  S O Matsumura; L Louie; M Louie; A E Simor
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods.

Authors:  C R Bonapace; R L White; L V Friedrich; J A Bosso
Journal:  Diagn Microbiol Infect Dis       Date:  2000-09       Impact factor: 2.803

3.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

4.  Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species.

Authors:  R E Lewis; D J Diekema; S A Messer; M A Pfaller; M E Klepser
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

5.  Comparison of techniques for measurement of in vitro antibiotic synergism.

Authors:  C W Norden; H Wentzel; E Keleti
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

6.  Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.

Authors:  B J Lang; S D Aaron; W Ferris; P C Hebert; N E MacDonald
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

Review 7.  Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.

Authors:  M H Kollef
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

Review 8.  The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection.

Authors:  G McCaughey; Df Gilpin; Js Elborn; Michael M Tunney
Journal:  Expert Rev Respir Med       Date:  2013-08       Impact factor: 3.772

9.  Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors.

Authors:  P C Taylor; F D Schoenknecht; J C Sherris; E C Linner
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

10.  Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis.

Authors:  Pablo San Gabriel; Juyan Zhou; Setareh Tabibi; Yunhua Chen; Marco Trauzzi; Lisa Saiman
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more
  101 in total

1.  In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

2.  Evaluation of the Activity of a Combination of Three Bacteriophages Alone or in Association with Antibiotics on Staphylococcus aureus Embedded in Biofilm or Internalized in Osteoblasts.

Authors:  Camille Kolenda; Jérôme Josse; Mathieu Medina; Cindy Fevre; Sébastien Lustig; Tristan Ferry; Frédéric Laurent
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  Escherichia coli Free Radical-Based Killing Mechanism Driven by a Unique Combination of Iron Restriction and Certain Antibiotics.

Authors:  Li Ma; Yongjun Gao; Anthony W Maresso
Journal:  J Bacteriol       Date:  2015-09-21       Impact factor: 3.490

4.  Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology.

Authors:  Thea Brennan-Krohn; Katherine A Truelson; Kenneth P Smith; James E Kirby
Journal:  J Antimicrob Chemother       Date:  2017-10-01       Impact factor: 5.790

5.  Evaluating the Antifungal Activity of α-Bisabolol in Association with NaCl on Fusarium oxysporum in Maize Grains.

Authors:  César A C de Medeiros; Ânderson de V Pinto; Josenildo C de Oliveira; Gezaíldo S Silva; Juliana M M Arrua; Igara O Lima; Fillipe de O Pereira
Journal:  Curr Microbiol       Date:  2021-01-03       Impact factor: 2.188

6.  Determining the Development of Persisters in Extensively Drug-Resistant Acinetobacter baumannii upon Exposure to Polymyxin B-Based Antibiotic Combinations Using Flow Cytometry.

Authors:  Fiona Hui-Sian Wong; Yiying Cai; Hui Leck; Tze-Peng Lim; Jocelyn Qi-Min Teo; Winnie Lee; Tse Hsien Koh; Thuan Tong Tan; Kar Wai Tan; Andrea Lay-Hoon Kwa
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

7.  Semi-mechanistic PK/PD modelling of fosfomycin and sulbactam combination against carbapenem-resistant Acinetobacter baumannii.

Authors:  S Mohd Sazlly Lim; A J Heffernan; J A Roberts; F B Sime
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

Review 8.  Improving therapy of severe infections through drug repurposing of synergistic combinations.

Authors:  Yu-Shan Cheng; Peter R Williamson; Wei Zheng
Journal:  Curr Opin Pharmacol       Date:  2019-08-24       Impact factor: 5.547

9.  Small-molecule inhibitors for the Prp8 intein as antifungal agents.

Authors:  Zhong Li; Anil Mathew Tharappel; Jimin Xu; Yuekun Lang; Cathleen M Green; Jing Zhang; Qishan Lin; Sudha Chaturvedi; Jia Zhou; Marlene Belfort; Hongmin Li
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-12       Impact factor: 11.205

10.  Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method.

Authors:  Thea Brennan-Krohn; James E Kirby
Journal:  J Vis Exp       Date:  2019-04-18       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.